
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Vericel Corp Ord (VCEL)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: VCEL (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $53.88
1 Year Target Price $53.88
7 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.73% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.80B USD | Price to earnings Ratio 255.5 | 1Y Target Price 53.88 |
Price to earnings Ratio 255.5 | 1Y Target Price 53.88 | ||
Volume (30-day avg) 8 | Beta 1.27 | 52 Weeks Range 33.09 - 63.00 | Updated Date 08/15/2025 |
52 Weeks Range 33.09 - 63.00 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-07-31 | When - | Estimate -0.03 | Actual -0.01 |
Profitability
Profit Margin 2.85% | Operating Margin (TTM) -3.21% |
Management Effectiveness
Return on Assets (TTM) 0.18% | Return on Equity (TTM) 2.59% |
Valuation
Trailing PE 255.5 | Forward PE 78.74 | Enterprise Value 1787844532 | Price to Sales(TTM) 7.25 |
Enterprise Value 1787844532 | Price to Sales(TTM) 7.25 | ||
Enterprise Value to Revenue 7.18 | Enterprise Value to EBITDA 110.44 | Shares Outstanding 50460200 | Shares Floating 49903124 |
Shares Outstanding 50460200 | Shares Floating 49903124 | ||
Percent Insiders 1.06 | Percent Institutions 111.05 |
Upturn AI SWOT
Vericel Corp Ord

Company Overview
History and Background
Vericel Corporation was founded in 1989. It focuses on advanced cell therapies for sports medicine and severe burn care.
Core Business Areas
- Sports Medicine: Vericel develops and commercializes autologous chondrocyte implantation (ACI) products for cartilage repair.
- Severe Burn Care: Vericel offers a cell therapy for the treatment of severe burns.
Leadership and Structure
The leadership team consists of the CEO, CFO, and other key executives. The organizational structure includes departments for R&D, manufacturing, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- MACI: MACI (autologous cultured chondrocytes on porcine collagen membrane) is used to repair cartilage defects in the knee. Vericel holds a significant market share within the ACI market. Competitors include surgical procedures like microfracture and other cartilage repair techniques. Estimated 80-85% market share within its niche.
- Epicel: Epicel (cultured epidermal autografts) is a permanent skin replacement for patients with severe burns. Epicel has less market share with other skin graphs available. Competitors include Integra LifeSciences (IART) and Mallinckrodt (MNK). Estimated market share 10-15% within its niche.
Market Dynamics
Industry Overview
The cell therapy market is experiencing growth, driven by advances in regenerative medicine and increasing demand for minimally invasive treatments.
Positioning
Vericel is a leader in the ACI market with MACI and has a niche position in severe burn care with Epicel. Its competitive advantage lies in its proprietary cell therapy technologies and established commercial infrastructure.
Total Addressable Market (TAM)
The TAM for cell therapies in sports medicine and burn care is estimated to be several billion dollars. Vericel is well positioned to capture a portion of this TAM with its established products and ongoing research and development.
Upturn SWOT Analysis
Strengths
- Established products with clinical data
- Strong brand recognition in the ACI market
- Proprietary cell therapy technologies
- Experienced management team
Weaknesses
- Limited product portfolio
- High manufacturing costs
- Reliance on a single manufacturing facility
- Reimbursement challenges
Opportunities
- Expansion of MACI to new indications
- Development of new cell therapies for other conditions
- Geographic expansion
- Strategic partnerships
Threats
- Competition from other cell therapy companies
- Regulatory changes
- Economic downturn
- Product liability claims
Competitors and Market Share
Key Competitors
- IART
- MNK
Competitive Landscape
Vericel has a strong position in the ACI market with MACI, but faces competition in the burn care market from companies like Integra LifeSciences and Mallinckrodt. Vericel's competitive advantage lies in its proprietary cell therapy technologies.
Major Acquisitions
None
- Year: 0
- Acquisition Price (USD millions): 0
- Strategic Rationale: N/A
Growth Trajectory and Initiatives
Historical Growth: Historically Vericel has grown with strong growth in the cartilage market.
Future Projections: Analyst projections suggest continued growth for Vericel, driven by increased adoption of MACI and potential new product launches.
Recent Initiatives: Recent initiatives include expanding MACI's reach and pursuing partnerships.
Summary
Vericel is a specialized biotech firm focused on cell therapies. Their cartilage repair product, MACI, dominates its market, and Epicel addresses burn treatment, though with more competition. Growth prospects are promising, but manufacturing costs and reimbursement hurdles pose challenges. Vericel's focused approach positions it well within niche regenerative medicine segments but exposes it to portfolio risk.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vericel Corp Ord
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 1997-02-04 | CEO, President & Director Mr. Dominick C. Colangelo Esq. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 357 | Website https://www.vcel.com |
Full time employees 357 | Website https://www.vcel.com |
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.